Cargando…
Activation of Coagulation by Lenalidomide-Based Regimens for the Treatment of Multiple Myeloma
We investigated the procoagulant effects of lenalidomide (Len)-based regimens in vitro focusing on tissue factor (TF) and phosphatidylserine (PS). We examined the effects of a pharmacological concentration of Len with or without the corticosteroid dexamethasone (Dex) and the proteasome inhibitor bor...
Autores principales: | Isozumi, Yu, Arai, Reina, Fujimoto, Kazumi, Koyama, Takatoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655994/ https://www.ncbi.nlm.nih.gov/pubmed/23696885 http://dx.doi.org/10.1371/journal.pone.0064369 |
Ejemplares similares
-
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021) -
Cell-based laboratory evaluation of coagulation activation by antineoplastic drugs for the treatment of lymphoid tumors
por: Tsunaka, Misae, et al.
Publicado: (2016) -
Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
por: Liberati, Anna Marina, et al.
Publicado: (2013) -
Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012) -
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)